Alpha-1 adrenergic receptor blockers for the treatment of lower urinary tract symptoms in women: A systematic review and meta-analysis

Do Kyung Kim, Joo Yong Lee, Jae Hung Jung, Jae Heon Kim, Yoon Soo Hah, Chang Hee Hong, Kang Su Cho

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

To assess the effectiveness of alpha-1 adrenergic receptor blockers (α1-blockers) in the treatment of female lower urinary tract symptoms (LUTS). Methods: A literature search was conducted using the PubMed/MEDLINE, Embase, and Cochrane Library databases. Fourteen studies with 1,319 patients were ultimately included. The study comprised 2 analyses: a comparison of urinary symptom scores, maximal flow rate (Qmax), and postvoid residual (PVR) urine volume before and after α1-blocker administration in 8 prospective, open-label studies and 5 randomized clinical trials (RCTs); and an evaluation of the same variables in α1-blocker and placebo groups in 4 RCTs. Results: The first meta-analysis showed that, following treatment, patients exhibited statistically significant symptom relief (mean difference [MD], -5.85; 95% confidence interval [CI], -7.71 to -3.99; P<0.00001), increased Qmax (MD, 3.67 mL/sec; 95% CI, 2.76-4.59 mL/sec; P<0.00001), and decreased PVR volume (MD, -28.46 mL; 95% CI, -34.99 to -21.93 mL; P<0.00001). In the second meta-analysis, α1-blockers demonstrated significant symptom relief relative to placebo (MD, -1.60; 95% CI, -2.68 to -0.51; P=0.004). However, no significant differences were observed in Qmax (MD, 0.05 mL/sec; 95% CI, -0.74 to 0.83 mL/sec, P=0.91) and PVR (MD, -8.10 mL; 95% CI, -32.32 to 16.12 mL, P=0.51) between the α1-blocker and placebo groups. Conclusions: These analyses suggest that α1-blockers are effective in the treatment of female LUTS patients. However, the effect of α1-blockers on female LUTS should be assessed according to the underlying cause, and the role of α1-blockers in combination therapy with other drugs should also be investigated.

Original languageEnglish
Pages (from-to)56-68
Number of pages13
JournalInternational Neurourology Journal
Volume23
Issue number1
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Adrenergic alpha-1 Receptor Antagonists
Lower Urinary Tract Symptoms
Adrenergic Antagonists
Adrenergic Receptors
Meta-Analysis
Confidence Intervals
Residual Volume
Placebos
Therapeutics
Randomized Controlled Trials
PubMed
MEDLINE
Libraries
Urine
Databases

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology
  • Urology

Cite this

Kim, Do Kyung ; Lee, Joo Yong ; Jung, Jae Hung ; Kim, Jae Heon ; Hah, Yoon Soo ; Hong, Chang Hee ; Cho, Kang Su. / Alpha-1 adrenergic receptor blockers for the treatment of lower urinary tract symptoms in women : A systematic review and meta-analysis. In: International Neurourology Journal. 2019 ; Vol. 23, No. 1. pp. 56-68.
@article{9917166faed44388a36be000eda48509,
title = "Alpha-1 adrenergic receptor blockers for the treatment of lower urinary tract symptoms in women: A systematic review and meta-analysis",
abstract = "To assess the effectiveness of alpha-1 adrenergic receptor blockers (α1-blockers) in the treatment of female lower urinary tract symptoms (LUTS). Methods: A literature search was conducted using the PubMed/MEDLINE, Embase, and Cochrane Library databases. Fourteen studies with 1,319 patients were ultimately included. The study comprised 2 analyses: a comparison of urinary symptom scores, maximal flow rate (Qmax), and postvoid residual (PVR) urine volume before and after α1-blocker administration in 8 prospective, open-label studies and 5 randomized clinical trials (RCTs); and an evaluation of the same variables in α1-blocker and placebo groups in 4 RCTs. Results: The first meta-analysis showed that, following treatment, patients exhibited statistically significant symptom relief (mean difference [MD], -5.85; 95{\%} confidence interval [CI], -7.71 to -3.99; P<0.00001), increased Qmax (MD, 3.67 mL/sec; 95{\%} CI, 2.76-4.59 mL/sec; P<0.00001), and decreased PVR volume (MD, -28.46 mL; 95{\%} CI, -34.99 to -21.93 mL; P<0.00001). In the second meta-analysis, α1-blockers demonstrated significant symptom relief relative to placebo (MD, -1.60; 95{\%} CI, -2.68 to -0.51; P=0.004). However, no significant differences were observed in Qmax (MD, 0.05 mL/sec; 95{\%} CI, -0.74 to 0.83 mL/sec, P=0.91) and PVR (MD, -8.10 mL; 95{\%} CI, -32.32 to 16.12 mL, P=0.51) between the α1-blocker and placebo groups. Conclusions: These analyses suggest that α1-blockers are effective in the treatment of female LUTS patients. However, the effect of α1-blockers on female LUTS should be assessed according to the underlying cause, and the role of α1-blockers in combination therapy with other drugs should also be investigated.",
author = "Kim, {Do Kyung} and Lee, {Joo Yong} and Jung, {Jae Hung} and Kim, {Jae Heon} and Hah, {Yoon Soo} and Hong, {Chang Hee} and Cho, {Kang Su}",
year = "2019",
month = "1",
day = "1",
doi = "10.5213/inj.1836188.094",
language = "English",
volume = "23",
pages = "56--68",
journal = "International Neurourology Journal",
issn = "2093-4777",
publisher = "Korean Association of Medical Journal Edirors",
number = "1",

}

Alpha-1 adrenergic receptor blockers for the treatment of lower urinary tract symptoms in women : A systematic review and meta-analysis. / Kim, Do Kyung; Lee, Joo Yong; Jung, Jae Hung; Kim, Jae Heon; Hah, Yoon Soo; Hong, Chang Hee; Cho, Kang Su.

In: International Neurourology Journal, Vol. 23, No. 1, 01.01.2019, p. 56-68.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Alpha-1 adrenergic receptor blockers for the treatment of lower urinary tract symptoms in women

T2 - A systematic review and meta-analysis

AU - Kim, Do Kyung

AU - Lee, Joo Yong

AU - Jung, Jae Hung

AU - Kim, Jae Heon

AU - Hah, Yoon Soo

AU - Hong, Chang Hee

AU - Cho, Kang Su

PY - 2019/1/1

Y1 - 2019/1/1

N2 - To assess the effectiveness of alpha-1 adrenergic receptor blockers (α1-blockers) in the treatment of female lower urinary tract symptoms (LUTS). Methods: A literature search was conducted using the PubMed/MEDLINE, Embase, and Cochrane Library databases. Fourteen studies with 1,319 patients were ultimately included. The study comprised 2 analyses: a comparison of urinary symptom scores, maximal flow rate (Qmax), and postvoid residual (PVR) urine volume before and after α1-blocker administration in 8 prospective, open-label studies and 5 randomized clinical trials (RCTs); and an evaluation of the same variables in α1-blocker and placebo groups in 4 RCTs. Results: The first meta-analysis showed that, following treatment, patients exhibited statistically significant symptom relief (mean difference [MD], -5.85; 95% confidence interval [CI], -7.71 to -3.99; P<0.00001), increased Qmax (MD, 3.67 mL/sec; 95% CI, 2.76-4.59 mL/sec; P<0.00001), and decreased PVR volume (MD, -28.46 mL; 95% CI, -34.99 to -21.93 mL; P<0.00001). In the second meta-analysis, α1-blockers demonstrated significant symptom relief relative to placebo (MD, -1.60; 95% CI, -2.68 to -0.51; P=0.004). However, no significant differences were observed in Qmax (MD, 0.05 mL/sec; 95% CI, -0.74 to 0.83 mL/sec, P=0.91) and PVR (MD, -8.10 mL; 95% CI, -32.32 to 16.12 mL, P=0.51) between the α1-blocker and placebo groups. Conclusions: These analyses suggest that α1-blockers are effective in the treatment of female LUTS patients. However, the effect of α1-blockers on female LUTS should be assessed according to the underlying cause, and the role of α1-blockers in combination therapy with other drugs should also be investigated.

AB - To assess the effectiveness of alpha-1 adrenergic receptor blockers (α1-blockers) in the treatment of female lower urinary tract symptoms (LUTS). Methods: A literature search was conducted using the PubMed/MEDLINE, Embase, and Cochrane Library databases. Fourteen studies with 1,319 patients were ultimately included. The study comprised 2 analyses: a comparison of urinary symptom scores, maximal flow rate (Qmax), and postvoid residual (PVR) urine volume before and after α1-blocker administration in 8 prospective, open-label studies and 5 randomized clinical trials (RCTs); and an evaluation of the same variables in α1-blocker and placebo groups in 4 RCTs. Results: The first meta-analysis showed that, following treatment, patients exhibited statistically significant symptom relief (mean difference [MD], -5.85; 95% confidence interval [CI], -7.71 to -3.99; P<0.00001), increased Qmax (MD, 3.67 mL/sec; 95% CI, 2.76-4.59 mL/sec; P<0.00001), and decreased PVR volume (MD, -28.46 mL; 95% CI, -34.99 to -21.93 mL; P<0.00001). In the second meta-analysis, α1-blockers demonstrated significant symptom relief relative to placebo (MD, -1.60; 95% CI, -2.68 to -0.51; P=0.004). However, no significant differences were observed in Qmax (MD, 0.05 mL/sec; 95% CI, -0.74 to 0.83 mL/sec, P=0.91) and PVR (MD, -8.10 mL; 95% CI, -32.32 to 16.12 mL, P=0.51) between the α1-blocker and placebo groups. Conclusions: These analyses suggest that α1-blockers are effective in the treatment of female LUTS patients. However, the effect of α1-blockers on female LUTS should be assessed according to the underlying cause, and the role of α1-blockers in combination therapy with other drugs should also be investigated.

UR - http://www.scopus.com/inward/record.url?scp=85064209502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064209502&partnerID=8YFLogxK

U2 - 10.5213/inj.1836188.094

DO - 10.5213/inj.1836188.094

M3 - Article

AN - SCOPUS:85064209502

VL - 23

SP - 56

EP - 68

JO - International Neurourology Journal

JF - International Neurourology Journal

SN - 2093-4777

IS - 1

ER -